DOP2006000074A - COMBINATION FOR THERAPY IN PROSTATE BENIGNA HYPERPLASIA - Google Patents

COMBINATION FOR THERAPY IN PROSTATE BENIGNA HYPERPLASIA

Info

Publication number
DOP2006000074A
DOP2006000074A DO2006000074A DO2006000074A DOP2006000074A DO P2006000074 A DOP2006000074 A DO P2006000074A DO 2006000074 A DO2006000074 A DO 2006000074A DO 2006000074 A DO2006000074 A DO 2006000074A DO P2006000074 A DOP2006000074 A DO P2006000074A
Authority
DO
Dominican Republic
Prior art keywords
hyperplasia
benigna
prostate
therapy
combination
Prior art date
Application number
DO2006000074A
Other languages
Spanish (es)
Inventor
Peter Serno
Helmut Haning
Erwin Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of DOP2006000074A publication Critical patent/DOP2006000074A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a un procedimiento novedoso para el tratamiento de síntomas en hiperplasia benigna de próstata. A este respecto se usan de forma simultánea: (1) un antagonista del adrenoreceptor a-1 en formulación de liberación controlada o un inhibidor de 5-a-reductasa y (2) un inhibidor de PDE 5 de GMPc en formulación de liberación controlada o un inhibidor de PDE 5 de GMPc con mayor tiempo de semivida.This invention relates to a novel method for the treatment of symptoms in benign prostatic hyperplasia. In this regard, the following are used simultaneously: (1) an a-1 adrenoceptor antagonist in a controlled release formulation or a 5-a-reductase inhibitor and (2) a cGMP 5 PDE inhibitor in a controlled release formulation or a cGMP 5 PDE inhibitor with longer half-life.

DO2006000074A 2005-04-13 2006-03-29 COMBINATION FOR THERAPY IN PROSTATE BENIGNA HYPERPLASIA DOP2006000074A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (en) 2005-04-13 2005-04-13 Combination therapy for benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
DOP2006000074A true DOP2006000074A (en) 2006-10-15

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000074A DOP2006000074A (en) 2005-04-13 2006-03-29 COMBINATION FOR THERAPY IN PROSTATE BENIGNA HYPERPLASIA

Country Status (22)

Country Link
EP (1) EP1888075A1 (en)
JP (1) JP2008535877A (en)
KR (1) KR20080007252A (en)
CN (1) CN101193638A (en)
AR (1) AR053575A1 (en)
AU (1) AU2006233567A1 (en)
BR (1) BRPI0610634A2 (en)
CA (1) CA2605224A1 (en)
CR (1) CR9427A (en)
DE (1) DE102005016981A1 (en)
DO (1) DOP2006000074A (en)
GT (1) GT200600145A (en)
IL (1) IL186604A0 (en)
MA (1) MA29683B1 (en)
MX (1) MX2007012567A (en)
PE (1) PE20061338A1 (en)
RU (1) RU2007141518A (en)
SV (1) SV2008002477A (en)
TN (1) TNSN07385A1 (en)
TW (1) TW200716122A (en)
UY (1) UY29473A1 (en)
WO (1) WO2006108519A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1968705A1 (en) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
WO2008005039A1 (en) * 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Solid compositions comprising tadalafil and at least one carrier
DE102007028869A1 (en) 2007-06-22 2008-12-24 Ratiopharm Gmbh A process for the preparation of a medicament containing tadalafil
SI2222300T1 (en) 2007-12-13 2014-11-28 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
JP5729808B2 (en) * 2007-12-13 2015-06-03 ヴァンダ ファーマシューティカルズ インコーポレイテッド Methods and compositions for treating alpha adrenergic receptor mediated conditions
US8654746B2 (en) 2010-04-26 2014-02-18 Intel Corporation Method, apparatus and system for fast session transfer for multiple frequency band wireless communication
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (en) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 Drug port cavity disintegrating tablet and preparation method thereof
EA039091B1 (en) * 2013-06-28 2021-12-02 Ханми Фарм. Ко., Лтд. Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
KR20210103589A (en) 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
KR101663238B1 (en) * 2013-11-15 2016-10-14 한미약품 주식회사 Complex solid formulation comprising tadalafil and amlodipine
WO2016003181A1 (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Composite preparation comprising active ingredient-containing film coating layer
WO2016003180A1 (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Composite preparation comprising 5-α-reductase inhibitor-containing film coating layer, and method for producing the composite preparation
PL3150201T3 (en) * 2014-06-30 2020-09-21 Hanmi Pharm. Co., Ltd. Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation
WO2016081772A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
AU2017244269A1 (en) * 2016-03-31 2018-10-11 Hanmi Pharm. Co., Ltd. Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate
KR101835506B1 (en) * 2016-10-25 2018-03-07 주식회사 에스텍파마 Rapid-acting mixture of tablet containing dutasteride and tadalafil
CN108066347B (en) * 2016-11-16 2021-02-02 深圳万和制药有限公司 Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride
KR101879133B1 (en) * 2017-07-11 2018-07-17 (주)동구바이오제약 Agents for preventing or treating urinary disease and preparing the same
TR201715231A2 (en) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
BRPI0610634A2 (en) 2010-07-13
JP2008535877A (en) 2008-09-04
CN101193638A (en) 2008-06-04
KR20080007252A (en) 2008-01-17
PE20061338A1 (en) 2007-01-28
AU2006233567A1 (en) 2006-10-19
SV2008002477A (en) 2008-02-08
DE102005016981A1 (en) 2006-10-19
RU2007141518A (en) 2009-05-20
TNSN07385A1 (en) 2009-03-17
CR9427A (en) 2007-12-17
WO2006108519A1 (en) 2006-10-19
UY29473A1 (en) 2006-11-30
EP1888075A1 (en) 2008-02-20
CA2605224A1 (en) 2006-10-19
MX2007012567A (en) 2007-12-10
MA29683B1 (en) 2008-08-01
GT200600145A (en) 2007-04-10
IL186604A0 (en) 2008-01-20
AR053575A1 (en) 2007-05-09
TW200716122A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
DOP2006000074A (en) COMBINATION FOR THERAPY IN PROSTATE BENIGNA HYPERPLASIA
AR048819A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
ECSP10010697A (en) DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD
ECSP099724A (en) USE OF PI3K-ALFA PYRIDOPIRIMIDINONE INHIBITORS IN CANCER TREATMENT
MX2009013729A (en) Imidazopyrazines as protein kinase inhibitors.
NO20083202L (en) ANG2 and VEFG inhibitor combinations
TR201819658T4 (en) Combination Adapalene And Benzoyl Peroxide To Treat Acne Lesions
NO20071078L (en) Antiviral compounds
NO20070866L (en) Antiviral compounds.
NO20080785L (en) Treatment of cancer
NO20062876L (en) Compositions for combined radio and chemotherapy, and methods
EA201890957A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMORS
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
ECSP088752A (en) FORMULATIONS FOR PARENTERAL ADMINISTRATION OF COMPOUNDS AND THEIR USES
EA201300742A1 (en) METHOD OF TREATING PROSTATIC CANCER WITH ANTAGONIST OF GONADOTROPIN-GRAINING HORMONE (GNRH) DEGARELIX
NO20080626L (en) Inhibitors of fibroblast activating protein alpha
EA200701995A1 (en) METHODS OF REDUCING CALCIFICATION
UY32769A (en) COMPOSITION FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA
TR201902884T4 (en) MMP ACTIVE VASCULAR DISSOLVING AGENTS.
CA2641347C (en) Indazole-heteroaryl derivatives
ECSP077247A (en) TRANS - CLOMPHENE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY, PROSTATIC CANCER, HYPOGONODISM, HIGH TRIGLICERIDS AND HIGH CHOLESTEROL
CO2022000270A2 (en) enzyme inhibitors
CO2022000266A2 (en) enzyme inhibitors
BR112017014914A2 (en) combined therapy for pulmonary hypertension
WO2007019065A3 (en) Adjuvant chemotherapy for anaplastic gliomas